Araújo A, et al. Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células Rev Port Pneumol 2008; 14(6):803-827

doi:10.1016/S0873-2159(15)30156-2

array:24 ["pii" => "S0873215915301562" "issn" => "08732159" "doi" => "10.1016/S0873-2159(15)30156-2" "estado" => "S350" "fechaPublicacion" => "2009-05-01" "aid" => "18" "copyright" => "Sociedade Portuguesa de Pneumologia/SPP" "copyrightAnyo" => "2009" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Rev Port Pneumol. 2009;15:560-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1760 "formatos" => array:3 [ "EPUB" => 199 "HTML" => 898 "PDF" => 663 ] ] "itemSiguiente" => array:19 [ "pii" => "S0873215915301458" "issn" => "08732159" "doi" => "10.1016/S0873-2159(15)30145-8" "estado" => "S350" "fechaPublicacion" => "2009-05-01" "aid" => "7" "copyright" => "Sociedade Portuguesa de Pneumologia/SPP" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "rev" "cita" => "Rev Port Pneumol. 2009;15:443-60" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2229 "formatos" => array:3 [ "EPUB" => 231 "HTML" => 1247 "PDF" => 751 ] ] "pt" => array:11 [ "idiomaDefecto" => true "cabecera" => "Artigo de Revisão/Review Article" "titulo" => "Avaliação da inflamação das vias aéreas. Vias áreas superiores e compartimento broncopulmonar" "tienePdf" => "pt" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "pt" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "443" "paginaFinal" => "460" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Airways inflammation evaluation. Upper and lower airways" ] ] "contieneResumen" => array:2 [ "pt" => true "en" => true ] "contienePdf" => array:1 [ "pt" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Luísa Geraldes, Ana Todo-Bom, Carlos Loureiro" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Luísa" "apellidos" => "Geraldes" ] 1 => array:2 [ "nombre" => "Ana" "apellidos" => "Todo-Bom" ] 2 => array:2 [ "nombre" => "Carlos" "apellidos" => "Loureiro" ] ] ] ] ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0873215915301458?idApp=UINPBA00004E" "url" => "/08732159/0000001500000003/v1_201509151500/S0873215915301458/v1_201509151500/pt/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S0873215915301446" "issn" => "08732159" "doi" => "10.1016/S0873-2159(15)30144-6" "estado" => "S350" "fechaPublicacion" => "2009-05-01" "aid" => "6" "copyright" => "Sociedade Portuguesa de Pneumologia/SPP" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Rev Port Pneumol. 2009;15:433-42" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2117 "formatos" => array:3 [ "EPUB" => 220 "HTML" => 1218 "PDF" => 679 ] ] "pt" => array:11 [ "idiomaDefecto" => true "cabecera" => "Artigo Original/Original Article" "titulo" => "Doenças pulmonares intersticiais: Acuidade diagnóstica e riscos da biópsia pulmonar cirúrgica" "tienePdf" => "pt" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "pt" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "433" "paginaFinal" => "442" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Interstitial lung disease: Diagnostic accuracy and safety of surgical lung biopsy" ] ] "contieneResumen" => array:2 [ "pt" => true "en" => true ] "contienePdf" => array:1 [ "pt" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Miguel Guerra, José António Miranda, Francisco Leal, Luís Vouga" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Miguel" "apellidos" => "Guerra" ] 1 => array:2 [ "nombre" => "José António" "apellidos" => "Miranda" ] 2 => array:2 [ "nombre" => "Francisco" "apellidos" => "Leal" ] 3 => array:2 [ "nombre" => "Luís" "apellidos" => "Vouga" ] ] ] ] ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0873215915301446?idApp=UINPBA00004E" "url" => "/08732159/0000001500000003/v1_201509151500/S0873215915301446/v1_201509151500/pt/main.assets" ] "pt" => array:9 [ "idiomaDefecto" => true "cabecera" => "Resposta ao Editor/Reply to the Editor" "titulo" => "Araújo A, et al. Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células Rev Port Pneumol 2008; 14(6):803-827" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "560" "paginaFinal" => "566" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803-827" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "lecturaRecomendada" => array:1 [ 0 => array:3 [ "vista" => "all" "titulo" => "Bibliografia/Bibliography" "seccion" => array:1 [ 0 => array:2 [ "vista" => "all" "bibliografiaReferencia" => array:17 [ 0 => array:3 [ "identificador" => "bb0005" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:1 [ 0 => "A. Araújo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Rev Port Pneumol" "fecha" => "2008" "volumen" => "14" "numero" => "6" "paginaInicial" => "803" "paginaFinal" => "827" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19023496" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bb0010" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Practice Guidelines in Oncology – v.2.2009 Non-Small Cell Lung Cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "National Comprehensive Cancer Network" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "WWW" => array:1 [ "link" => "http://www.nccn.org/professional/physician_gls/f_guidelines.asp" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bb0015" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Updated guide to the methods of technology appraisal" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "National Institute for Health and Clinical Excellence" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "WWW" => array:2 [ "link" => "http://nice.org.uk/media/B52/A7/TAMethodsGuideUpsdatedJune2008.pdf" "fecha" => "June 2008" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bb0020" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Erlotinib in previously treated non-small cell lung cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "F.A. Shepherd" 1 => "J. Pereira" 2 => "T. Ciuleanu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa050753" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2005" "volumen" => "353" "paginaInicial" => "123" "paginaFinal" => "132" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16014882" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bb0025" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:1 [ 0 => "F.A. Shepherd" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/jco.2000.18.10.2095" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2000" "volumen" => "18" "numero" => "10" "paginaInicial" => "2095" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10811675" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bb0030" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "N. Hanna" 1 => "F.A. Shepherd" 2 => "F.V. Fossela" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2004.08.163" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2004" "volumen" => "22" "paginaInicial" => "1589" "paginaFinal" => "1597" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15117980" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bb0035" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "W. Kotowa" 1 => "U. Gatzemeier" 2 => "O. Pirk" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Journal of Medical Economics" "fecha" => "2007" "volumen" => "10" "paginaInicial" => "255" "paginaFinal" => "271" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bb0040" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pemetrexed for the treatment of non-small-cell lung cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "National Institute for Health and Clinical Excellence" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "WWW" => array:2 [ "link" => "http://www.nice.org.uk/TA124" "fecha" => "August 2007" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bb0045" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chemotherapeutic management of stage IV non-small cell lung cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M.A. Socinski" 1 => "D.E. Morris" 2 => "G.A. Masters" 3 => "R. Lilenbaum" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Chest" "fecha" => "2003" "volumen" => "123" "paginaInicial" => "226" "paginaFinal" => "243" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bb0050" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "New avenues for second-line treatment of metastatic non-small-cell lung cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "C. Gridelli" 1 => "P. Maione" 2 => "A. Rossi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/14737140.9.1.115" "Revista" => array:7 [ "tituloSerie" => "Expert Rev Anticancer Ther" "fecha" => "2009" "volumen" => "9" "numero" => "1" "paginaInicial" => "115" "paginaFinal" => "124" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19105711" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bb0055" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Considerations for second-line therapy of non-small cell lung cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "T.E. Stinchcombe" 1 => "M.A. Socinski" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "On-cologist" "fecha" => "2008" "volumen" => "13" "numero" => "Suppl 1" "paginaInicial" => "28" "paginaFinal" => "36" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bb0060" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cost-effectiveness of erlotinib vs docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J. Carlson" 1 => "N. Oestreicher" 2 => "D.P. Lubeck" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Journal of Clinical Oncology" "fecha" => "2007" "volumen" => "25" "numero" => "Suppl 18" "paginaInicial" => "425" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bb0065" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer: a French observational study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "C. Chouaid" 1 => "A. Vergnenegre" 2 => "A. Moser" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Value in Health" "fecha" => "2007" "volumen" => "10" "paginaInicial" => "A322" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bb0070" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Economic evaluation of erlotinib, docetaxel and pemetrexed as second line treatment in patients with advanced non-small-cell lung cancer (NSCLC): A cost-minimization in Italian hospitals" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S. Capri" 1 => "A. Morabito" 2 => "G. Carillio" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Value in Health" "fecha" => "2007" "volumen" => "10" "paginaInicial" => "A333" "itemHostRev" => array:3 [ "pii" => "S0165032713008598" "estado" => "S300" "issn" => "01650327" ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bb0075" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cost-minimization analysis of erlotinib versus docetaxel or pemetrexed as second-line therapy for non-small-cell lung cancer (NSCLC) from the perspective of a private payer in Brazil" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S. Stefani" 1 => "M.G. Saggia" 2 => "E.A. Santos" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Value in Health" "fecha" => "2007" "volumen" => "10" "paginaInicial" => "A332k" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bb0080" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cost-effectiveness analysis of erlotinib compared with docetaxel and pemetrexed for second-line treatment of advanced non-small cell lung cancer (NSCLC) in Taiwan" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "T.C. Hsia" 1 => "G.C. Chang" 2 => "Y.M. Chen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Value in Health" "fecha" => "2007" "volumen" => "10" "paginaInicial" => "A325" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bb0085" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacoeconomic analysis of erlotinib compared with docetaxel for the treatment of relapsed non-small-cell lung cancer (NSCLC) in Turkey. PCN77" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "O. Batigun" 1 => "E. Yildrim" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Value in Health" "fecha" => "2007" "volumen" => "10" "paginaInicial" => "A234" ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "pt" "url" => "/08732159/0000001500000003/v1_201509151500/S0873215915301562/v1_201509151500/pt/main.assets" "Apartado" => array:4 [ "identificador" => "43855" "tipo" => "SECCION" "pt" => array:2 [ "titulo" => "Resposta ao Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "pt" ] "PDF" => "https://static.elsevier.es/multimedia/08732159/0000001500000003/v1_201509151500/S0873215915301562/v1_201509151500/pt/main.pdf?idApp=UINPBA00004E&text.app=https://journalpulmonology.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0873215915301562?idApp=UINPBA00004E"]

Article information

Download PDF

Statistics

Full text is only aviable in PDF

Bibliografia/Bibliography

[1.]

A. Araújo, et al.

Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células.

Rev Port Pneumol, 14 (2008), pp. 803-827

Medline

[2.]

National Comprehensive Cancer Network.

Practice Guidelines in Oncology – v.2.2009 Non-Small Cell Lung Cancer.

http://www.nccn.org/professional/physician_gls/f_guidelines.asp

[3.]

National Institute for Health and Clinical Excellence.

Updated guide to the methods of technology appraisal.

(June 2008)http://nice.org.uk/media/B52/A7/TAMethodsGuideUpsdatedJune2008.pdf

[4.]

F.A. Shepherd, J. Pereira, T. Ciuleanu, et al.

Erlotinib in previously treated non-small cell lung cancer.

N Engl J Med, 353 (2005), pp. 123-132

http://dx.doi.org/10.1056/NEJMoa050753 | Medline

[5.]

F.A. Shepherd, et al.

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based therapy.

J Clin Oncol, 18 (2000), pp. 2095

http://dx.doi.org/10.1200/jco.2000.18.10.2095 | Medline

[6.]

N. Hanna, F.A. Shepherd, F.V. Fossela, et al.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

J Clin Oncol, 22 (2004), pp. 1589-1597

http://dx.doi.org/10.1200/JCO.2004.08.163 | Medline

[7.]

W. Kotowa, U. Gatzemeier, O. Pirk, et al.

A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective.

Journal of Medical Economics, 10 (2007), pp. 255-271

[8.]

National Institute for Health and Clinical Excellence.

Pemetrexed for the treatment of non-small-cell lung cancer.

(August 2007)http://www.nice.org.uk/TA124

[9.]

M.A. Socinski, D.E. Morris, G.A. Masters, R. Lilenbaum.

Chemotherapeutic management of stage IV non-small cell lung cancer.

Chest, 123 (2003), pp. 226-243

[10.]

C. Gridelli, P. Maione, A. Rossi, et al.

New avenues for second-line treatment of metastatic non-small-cell lung cancer.

Expert Rev Anticancer Ther, 9 (2009), pp. 115-124

http://dx.doi.org/10.1586/14737140.9.1.115 | Medline

[11.]

T.E. Stinchcombe, M.A. Socinski.

Considerations for second-line therapy of non-small cell lung cancer.

On-cologist, 13 (2008), pp. 28-36

[12.]

J. Carlson, N. Oestreicher, D.P. Lubeck, et al.

Cost-effectiveness of erlotinib vs docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology, 25 (2007), pp. 425

[13.]

C. Chouaid, A. Vergnenegre, A. Moser, et al.

Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer: a French observational study.

Value in Health, 10 (2007), pp. A322

[14.]

S. Capri, A. Morabito, G. Carillio, et al.

Economic evaluation of erlotinib, docetaxel and pemetrexed as second line treatment in patients with advanced non-small-cell lung cancer (NSCLC): A cost-minimization in Italian hospitals.

Value in Health, 10 (2007), pp. A333

[15.]

S. Stefani, M.G. Saggia, E.A. Santos.

Cost-minimization analysis of erlotinib versus docetaxel or pemetrexed as second-line therapy for non-small-cell lung cancer (NSCLC) from the perspective of a private payer in Brazil.

Value in Health, 10 (2007), pp. A332k

[16.]

T.C. Hsia, G.C. Chang, Y.M. Chen, et al.

Cost-effectiveness analysis of erlotinib compared with docetaxel and pemetrexed for second-line treatment of advanced non-small cell lung cancer (NSCLC) in Taiwan.

Value in Health, 10 (2007), pp. A325

[17.]

O. Batigun, E. Yildrim.

Pharmacoeconomic analysis of erlotinib compared with docetaxel for the treatment of relapsed non-small-cell lung cancer (NSCLC) in Turkey. PCN77.

Value in Health, 10 (2007), pp. A234

Indexed in:

Follow us:

Indexed in:

Follow us:

Subscribe to our newsletter